Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Background Acral melanoma is a rare melanoma subtype with poor prognosis.Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1) agents nivolumab and pembrolizumab.There is therefore an absence of prospective clinical trial eviden